Clinical Trials
8 trialsNCT03666000 2026-02-02
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Imugene Limited
Phase 1 Recruiting
NCT05336409 2025-12-18
ELiPSE-1
Century Therapeutics, Inc.
Phase 1 Terminated
NCT05400122 2025-11-12
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Phase 1 Suspended
NCT07225439 2025-11-06
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT00968760 2023-12-19
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00952237 2018-04-25
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT00697671 2013-07-16
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00010192 2013-06-06
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Completed